Is SkyePharma PLC A Better Buy Than Shire PLC Or Hikma Pharmaceuticals Plc?

Can upstart SkyePharma PLC (LON:SKP) continue to leap ahead of Shire PLC (LON:SHP) and Hikma Pharmaceuticals Plc (LON:HIK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pharmaceutical stocks SkyePharma (LSE: SKP), Shire (LSE: SHP) (NASDAQ: SHPG.US) and Hikma Pharmaceuticals (LSE: HIK) have risen by an average of 212% over the last two years.

The gains haven’t been equal, though. Investors in SkyePharma can rightfully feel smug, as their company has risen by 370% since June 2013, compared to 104% for Hikma and 165% for Shire.

The only problem is that SkyePharma shares are down by 17% so far in 2015. Is it time to take profits, or can this smaller firm continue to outperform its larger peers?

Going ex-growth?

All three of these firms have been impressive growth buys. Yet there are signs that earnings per share (eps) growth may be slowing at each firm:

Company

2015 eps growth*

2016 eps growth*

Shire

-39%

+17%

Hikma Pharmaceuticals

-9%

+15%

SkyePharma

+125%

+9%

*Reuters consensus forecasts

SkyePharma still has the most promising growth outlook. The firm issued a trading update on Thursday morning confirming that it expected to match full-year guidance.

However, it looks like next year could see SkyePharma’s rapid growth rate slow to quite pedestrian levels.

In a similar vein, both Shire and Hikma are expected to have a tough year in 2015, mainly due to falling profits from established products and exchange rate effects. Although earnings are expected to pick up in 2016, it’s not clear to me whether either company will regain its former momentum.

Key buying signal

We can’t forecast the future, but we can use the valuation of each of these firms to help decide which, if any, are currently an attractive buy.

Company

2015 forecast P/E

2016 forecast P/E

Shire

22.1

18.8

Hikma Pharmaceuticals

21.5

19.0

SkyePharma

15.5

14.2

Based on these forecasts and current expectations for earnings growth, I don’t think that any of these companies are obviously cheap.

Share prices tend to rise and fall when companies exceed, or miss, expectations. These expectations are already high for Shire and Hikma, so there’s a greater risk of disappointment.

I’d be tempted to pick SkyePharma as the pick of the bunch, because its more modest valuation and smaller size leaves more room for outperformance.

The firm’s current valuation reflects the market’s more measured expectations. These should be easier to meet and perhaps beat. SkyePharma’s core new product, flutiform, is still being rolled out globally, and should drive earnings growth for some time to come.

It’s worth commenting that if you ignore exceptional variations, all three of these companies have historically generated an operating profit margin of 20-30%. SkyePharma has been a little less consistent in this department, but I think that its more stable outlook and strong finances should now mean that profitability becomes more consistent.

Today’s best buy?

In today’s trading update, Peter Grant, SkyePharma’s chief executive, said that “further launches and product approvals” were building momentum for the future.

Although this remark could equally have been made by the bosses of Shire and Hikma, both of which I rate as a hold, I believe that SkyePharma’s much more modest valuation provides investors with the opportunity to profit from this growing momentum.

As a result, I’d say that SkyePharma is an attractive buy and well worth holding onto for existing shareholders.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »